Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Media Corporation Series C Liberty Formula One Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $23.11B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is far larger — about 2.2× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Liberty Media Corporation Series C Liberty Formula One Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| FWONK | PCVX | |
|---|---|---|
Market Cap | $23.11B | $10.51B |
Volume | 3,394,596 | 2,644,694 |
Sector | Media | Health |
52-Week High | $106.66 | $73.82 |
52-Week Low | $81.42 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $26.57B | $9.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Liberty Media Corporation Series C Liberty Formula One Common Stock
Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
